Page last updated: 2024-08-24

valsartan and Prediabetes

valsartan has been researched along with Prediabetes in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Califf, RM; Gray, AM; Holman, RR; Leal, J; Li, Y; Patel, R; Reed, SD; Rivero-Arias, O; Schulman, KA1
Goldstein, BA; Holman, RR; Pagidipati, NJ; Pencina, MJ; Phelan, M; Stuart, EA1
Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR1
Bakris, GL; Cuadra, RH; Kupfer, S; Lloyd, E; White, WB1
Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH1
Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L1
Ofili, EO; Purkayastha, D; Samuel, R; Sowers, JR; Zappe, DH1

Trials

6 trial(s) available for valsartan and Prediabetes

ArticleYear
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data.
    Diabetes care, 2020, Volume: 43, Issue:10

    Topics: Adult; Age of Onset; Aged; Benchmarking; Cardiometabolic Risk Factors; Cardiovascular Diseases; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Mortality; Prediabetic State; Primary Prevention; Quality of Life; Quality-Adjusted Life Years; United Kingdom; United States; Valsartan

2020
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
    Circulation. Heart failure, 2016, Volume: 9, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
    Journal of hypertension, 2016, Volume: 34, Issue:4

    Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Imidazoles; Male; Middle Aged; Oxadiazoles; Prediabetic State; Tetrazoles; Valsartan

2016
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
    Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:12

    Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Risk Factors; Tetrazoles; Valine; Valsartan; Young Adult

2008
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Cardiovascular therapeutics, 2010, Volume: 28, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan

2010
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
    American journal of therapeutics, 2013, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperglycemia; Hypertension; Insulin; Intention to Treat Analysis; Male; Middle Aged; Obesity, Abdominal; Prediabetic State; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People

2013

Other Studies

1 other study(ies) available for valsartan and Prediabetes

ArticleYear
An outcome model approach to transporting a randomized controlled trial results to a target population.
    Journal of the American Medical Informatics Association : JAMIA, 2019, 05-01, Volume: 26, Issue:5

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan

2019